Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living Medicines
CAMBRIDGE, Mass., Jan. 31, 2023 /PRNewswire/ — Kytopen, a biotechnology company leading advancements in high-throughput cellular and genome engineering platforms, today announced a partnership with the pioneering transfection company, Mirus Bio, pairing their technologies to resolve challenges related to the delivery of complex genetic materials to living human cells. “Gene-modified cell therapies hold great promise for patients. […]
Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality
DUBLIN, Ireland and CAMBRIDGE, Mass., Jan. 16, 2023 (GLOBE NEWSWIRE) — Avectas, a cell engineering technology leader, announces the launch of the Solupore platform at the Advanced Therapies Week, Miami Beach Convention Centre, January 17th – 20th, 2023, Booth # 331 The Solupore non-viral delivery system enables the clinical manufacturing of advanced cell therapies differentiated by unparalleled cell health and superior […]
Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, Inc., today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen […]
Cell and Gene Therapy Companies Leverage GenScript’s cGMP sgRNA Capability to Accelerate Speed to Market
PISCATAWAY, N.J., Dec. 15, 2022 /PRNewswire/ — GenScript USA Inc., the world’s leading life-science service provider, recently expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. GenScript’s 400,000 square-foot cGMP facility enables next-generation gene and cell therapy R&D programs to advance IND filings and clinical trials. “We are […]
Lyell Immunopharma to Participate in BofA Securities Biotech Conference
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the virtual BofA Securities 2022 Biotech SMID Cap Conference on Thursday, Dec. 8 […]
Bone Marrow Transplant and Cell Therapies Unit at Tampa General Hospital Brings More Treatment Options to Cancer Patients
TAMPA, Fla., Oct. 3, 2022 /PRNewswire/ — As part of its commitment to world-class, innovative cancer care for the Tampa Bay region and beyond, Tampa General Hospital (TGH) Cancer Institute has established an adult Bone Marrow Transplant (BMT) and Cell Therapies unit that focuses on treating patients with aggressive blood cancers such as leukemias, lymphomas, multiple […]
Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that a poster describing the first-in-human Phase 1 trial design for LYL797, Lyell’s ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic […]
RoslinCT and Lykan Bioscience Combine to Create Leading Advanced Cell Therapy CDMO
EDINBURGH, UK AND HOPKINTON, MA, 4 August 2022 – RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience (‘Lykan’), an innovative CDMO focused on cell-based therapies, today announce that they have entered into a business combination agreement to form a global leading innovative […]
Cellino’s Path Towards Personalized Cell Therapies at Scale
Meet Cellino, a Leaps portfolio company that aims to make personalized cell therapies available at scale through advanced manufacturing. Founder and CEO Nabiha Saklayen shares her insight into the potential of cell therapies to change the course or even cure some of the most challenging diseases. Cellino’s unique interdisciplinary approach aims to automate the manufacturing […]
GoodCell Offers Personal Biobanking Early Adopter Discount for a Limited Time
Waltham, MA, June 13, 2022 (GLOBE NEWSWIRE) — Today, GoodCell, a life sciences company, is announcing a limited-time early adopter discount for Personal Biobanking, a proactive, preventative healthcare service that allows members to store their own stem cells for future potential personalized cell therapies. GoodCell’s Personal Biobanking—similar to cord blood banking—is a subscription service. With the […]